Latest news with #AlexThompsonCFA
Business Insider
21 hours ago
- Business
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)
In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), with a price target of $52.00. The company's shares closed last Friday at $16.86. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Travere Therapeutics, and Viridian Therapeutics. According to TipRanks, Thompson CFA has an average return of -3.4% and a 43.20% success rate on recommended stocks. Dianthus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $46.75, which is a 177.37% upside from current levels. In a report released on June 18, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target. The company has a one-year high of $32.27 and a one-year low of $13.37. Currently, Dianthus Therapeutics has an average volume of 319.1K.
Business Insider
26-05-2025
- Business
- Business Insider
Kymera Therapeutics (KYMR) Initiated with a Buy at Stifel Nicolaus
In a report released today, Alex Thompson CFA from Stifel Nicolaus initiated coverage with a Buy rating on Kymera Therapeutics (KYMR – Research Report) and a price target of $55.00. The company's shares closed last Friday at $29.49. Confident Investing Starts Here: Thompson CFA covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Argenx Se, and Travere Therapeutics. According to TipRanks, Thompson CFA has an average return of -5.8% and a 40.68% success rate on recommended stocks. In addition to Stifel Nicolaus, Kymera Therapeutics also received a Buy from UBS's Eliana Merle in a report issued on May 13. However, on May 12, Bank of America Securities reiterated a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). Based on Kymera Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.1 million and a GAAP net loss of $65.58 million. In comparison, last year the company earned a revenue of $10.29 million and had a GAAP net loss of $48.56 million Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KYMR in relation to earlier this year. Most recently, in March 2025, Jeremy Chadwick, the COO of KYMR sold 1,383.00 shares for a total of $42,103.92.
